Scientific Consultant, Living Tumor Laboratory
Honorary Associate Professor, Urologic Sciences, University of British Columbia
Emeritus Senior Scientist, Department of Cancer Endocrinology, BC Cancer Agency
Dr. Gout is an Emeritus Senior Scientist of the BC Cancer Agency Research Centre and an Honorary Associate Professor of the University of British Columbia. After his retirement as Head of the Department of Cancer Endocrinology, he has acted as a Scientific Consultant for the Living Tumor Laboratory since 2005. Dr. Gout obtained a PhD degree in Biochemistry from the State University of Leiden, The Netherlands. He has worked for more than 40 years in Cancer Research and has extensive experience in the areas of protein hormone research, cell culturing, bioassays and cancer chemotherapy.
Sze Ue Iris Luk, Hui Xue, Hongwei Cheng, Dong Lin, Peter W Gout, Ladan Fazli, Colin C Collins, Martin E Gleave, Yuzhuo Wang. The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis. Oncotarget. 2014 Jul 17. [Epub ahead of print]
Yan Ting Chiang, Peter W Gout, Colin C Collins, Yuzhuo Wang. Prostate cancer metastasis‑driving genes: hurdles and potential approaches in their identification. Asian J Androl. 2014 Jul-Aug;16(4):545-8.
Dong Lin, Hui Xue, Yuwei Wang, Rebecca Wu, Akira Watahiki, Xin Dong, Hongwei Cheng, Alexander W Wyatt, Colin C Collins, Peter W Gout, Yuzhuo Wang. Next generation patient-derived prostate cancer enograft models. Asian J Androl. 2014 May-Jun;16(3):407-12.
Sifeng Qu, Kendric Wang, Hui Xue, Yuwei Wang, Rebecca Wu, Chengfei Liu, Allen C. Gao, Peter W. Gout, Colin C. Collins, Yuzhuo Wang. Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. Mol Oncol. 2014 Mar;8(2):311-22.
Dong Lin, Alexander W Wyatt, Hui Xue, Yuwei Wang, Xin Dong, Anne Haegert, Rebecca Wu, Sonal Brahmbhatt, Fan Mo, Lina Jong, Robert H. Bell, Shawn Anderson, Antonio Hurtado-Coll,
Ladan Fazli, Manju Sharma, Himisha Beltran, Mark A Rubin, Michael E Cox, Peter W Gout, James Morris, Larry Goldenberg, Stanislav V Volik, Martin E Gleave, Colin C Collins, Yuzhuo Wang. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res, 2014 Feb 15;74(4):1272-83
Yan Ting Chiang, Kendric Wang, Ladan Fazli, Robert Z Qi, Martin E Gleave, Colin C Collins, Peter W Gout, Yuzhuo Wang. GATA2 as a potential metastasis-driving gene in prostate cancer. Oncotarget. 2014 Jan 30;5(2):451-61.
Stephen Yiu Chuen Choi, Colin C Collins, Peter W Gout and Yuzhuo Wang. Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? J Pathol. 2013 Aug;230(4):350-5.
Dong Lin, Peter W. Grout, Yuzhuo Wang, Lessons from in-vivo models of castration-resistant prostate cancer, Curr Opin rol. 2013 May;23(3):214-9
Christopher G Low, Iris S U Luk, Dong Lin, Ladan Fazli, Kuo Yang, Yong Xu, Martin Gleave, Peter W Gout, Yuzhuo Wang. BIRC6 protein, an inhibitor of apoptosis: role in survival of human prostate cancer cells. PLoS One. 2013;8(2): Epub 2013 Feb 8.
Xin Dong, Dong Lin, Chris Low, Emily A Vucic, John C. English, John Yee, Nevin Murray, Wan L. Lam, victor Ling, Stephen Lam, Peter W. Gout, Yuzhuo Wang. Elevated Expression of BIRC6 Protein in Non–Small-Cell Lung Cancers is Associated with Cancer Recurrence and Chemoresistance. J Thorac Oncol. 2013 Feb;8(2):161-70.
Jan Lewerenz, Sandra J Hewett, Ying Huang, Maria Lambros, Peter W Gout, Peter W Kalivas, Ann Massie, Ilse Smolders, Axel Methner, Mathias Pergande, Sylvia B Smith, Vadivel Ganapathy, Pamela Maher. The Cystine/Glutamate Antiporter System x(c)(-) in Health and Disease: From Molecular Mechanisms to Novel Therapeutic Opportunities. Antioxid Redox Signal. 2013 Feb 10;18(5):522-55.
Stephen Yiu Chuen Choi, Peter W. Gout, Colin C. Collin, Yuzhuo Wang. Epithelial immune cell-like transition (EIT): A proposed transdifferentiation process underlying immune-suppressive activity of epithelial cancers. Differentiation. 2012 Jun;83(5):293-8.
Gout PW, Wang YZ. Drug sensitivity testing for personalized lung cancer therapy. J Thorac Dis 2012 Feb;4(1):17-8.
Collins CC, Volik SV, Lapuk A, Wang Y, Gout PW, Wu C, Xue H, Cheng H, Haegert A, Bell RH, Brahmbhatt S, Anderson S, Fazli L, Hurtado-Coll A, Rubin MA, Demichelis F, Beltran H, Hirst M, Marra MA, Maher CA, Chinnaiyan AM, Gleave ME, Bertino JR, Lubin M, Wang YZ. Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenine Phosphorylase (MTAP), an Exploitable Tumor Target. Mol Cancer Ther. 2012 Jan 17. [Epub ahead of print]
Watahiki A, Wang Y, Morris J, Dennis K, O'Dwyer HM, Gleave M, Gout PW, Wang Y. MicroRNAs associated with metastatic prostate cancer. PLoS One. 2011;6(9):e24950. Epub 2011 Sep 30.
Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok S, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard S, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, and Birrer MJ, Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers.PLoS One. 2011;6(7):e21121.
Wei-Lin Tung, Yuwei Wang, Peter W Gout, Dean-Mo Liu, Martin Gleave, Yuzhuo Wang. Use of Irinotecan for Treament of Small Cell Carcinoma of the Prostate. The Prostate 14 OCT 2010
Dong Lin, Jane Bayani, Yuwei Wang, Marianne D. Sadar, Maisa Yoshimoto, Peter W. Gout, Jeremy A. Squire, Yuzhuo Wang PhD, Yuzhuo Wang. Development of Metastatic and Non-Metastatic Tumor Lines From a Patient’s Prostate Cancer Specimen - Identification of a Small Subpopulation With Metastatic Potential in the Primary Tumor. The Prostate 70:1636 -1644, 2010.
Lo M, Ling V, Low C, Wang YZ, Gout PW. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Curr Oncol 2010 Jun;17(3):9-16.
Lo M, Ling V, Low C, Wang YZ, Gout PW. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Current Oncology 17 (3): 9-16, 2010.
Dong X, Guan J, English J, Flint J, Yee J, Evans K, Murray N, MacAulay C, Ng R, Gout PW, Lam W, Laskin J, Ling V, Lam S, Wang YZ. Patient-derived first generation xenografts of non-small cell lung cancers: Promising tools for predicting drug responses for personalized chemotherapy. Clin. Cancer Research 16:1442-1451, 2010.
J. Guan, M. Lo, P Dockery, S. Mahon, C karp, A. Buckley , S. Lam , P. W. Gout, Y. Z. Wang. The xc- Cystine Transporter as a Therapeutic Target for Small Cell Lung Cancer: Use of Sulfasalazine. Cancer Chemotherapy and Pharmacology, 64(3): 463-72, 2009.
D. Lin, A. Watahiki, J. Bayani, F. Zhang, L. Liu, V. Ling, M. Sadar, J. English, L. Fazli, A. So, P. Gout, M. Gleave, J. A. Squire and Y.Z. Wang. ASAP1, a Gene at 8q24, is Associated with Prostate Cancer Metastasis. Cancer Research. 68: 4352-4359. 2008.
Lo M, Wang YZ, Gout PW. The xc- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol 2008;215:593-602.
Lo M, Ling V, Wang YZ, Gout PW. The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br J Cancer 2008;99(3):464-472.
D. Doxsee, P Gout, T. Kurita, M. Lo, A. Buckley, Y. Wang, H. Xue, C. Karp, J. C. Cutz, G. Cunha, and Y.Z. Wang. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate 67 (2): 162-171, 2007.
J. C. Cutz, J. Guan, J. Bayani, H. Xue, M. Sutcliffe, J. English, J. Flint, J. LeRiche, J. Yee, J Squire, P. W. Gout, S. Lam, and Y.Z. Wang. Establishment in SCID Mice of Subrenal Capsule Xenografts and Transplantable Tumor Lines from a Variety of Primary Human Lung Cancers: Potential Models for Studying Tumor Progression-Related Changes. Clin. Cancer Research. 12 (13): 4043-4054, 2006.
Cheng-Han Lee, Hui Xue, Margaret Sutcliffe, Peter W Gout, David G Huntsman, Dianne M Miller, C Blake Gilks, Y Z Wang. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gyn. Oncol. 96 (1): 48-55, 2005.
Gout PW, Buckley AR, Simms CR, Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc- cystine transporter: A new action for an old drug. Leukemia 2001;15(10):1633-1640.
Gout PW, Kang YJ, Buckley DJ, Bruchovsky N, Buckley AR. Increased cystine uptake capability associated with malignant progression of Nb2 lymphoma cells. Leukemia 1997;11:1329-1337.
Gout PW, Horsman DE, Fox K, de Jong G, Ma S, Bruchovsky N. The rat Nb2 lymphoma: A novel model for tumor progression. Anticancer Res 1994;14:2485‑2492. [Abstract]
Luck DN, Gout PW, Beer CT, Smith M. Bioactive recombinant methionyl bovine prolactin: structure‑function studies using site‑specific mutagenesis. Mol Endocrinol 1989;3:822‑831. [Abstract]
Tanaka T, Shiu RPC, Gout PW, Beer CT, Noble RL, Friesen HG. A new, sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum. J Clin Endocrinol Metab 1980;51:1058‑1063. [Abstract]
Gout PW, Beer CT, Noble RL. Prolactin‑stimulated growth of cell cultures established from malignant Nb rat lymphomas. Cancer Res 1980;40:2433‑2436.
Gout PW, Wijcik LL, Beer CT. Differences between vinblastine and vincristine in distribution in the blood of rats and binding by platelets and malignant cells. Europ J Cancer 1978;14:1167‑1178.